Causes and Risk Factors

The exact cause of JSpA is unknown, but research points to a combination of genetic, immunologic, and environmental factors.

Genetic predisposition

• HLA‑B27: The single most important genetic marker; 70‑90 % of children with ERA are HLA‑B27 positive.^[4]
• Other genes: Variants in ERAP1, IL23R, and TNF‑α promoter regions modestly increase risk.

Immune system dysfunction

Abnormal activation of Th17 cells and elevated cytokines (TNF‑α, IL‑17, IL‑23) drive chronic inflammation in joints and entheses.

Environmental triggers

• Infections: Certain bacterial infections (e.g., Chlamydia trachomatis, gastrointestinal pathogens) may trigger reactive arthritis, a subtype of JSpA.
• Mechanical stress: Repetitive micro‑trauma at entheses (common in athletes) can precipitate symptoms in genetically susceptible children.

Risk factors

• Male sex (especially for ERA)
• Positive family history of HLA‑B27 or spondyloarthritis
• Early onset of enthesitis or dactylitis (swollen “sausage” digits)
• Co‑existing psoriasis or IBD

Diagnosis

Diagnosing JSpA requires a combination of clinical assessment, imaging, laboratory studies, and exclusion of other conditions.

Clinical criteria

Most clinicians use the International League of Associations for Rheumatology (ILAR) classification for juvenile idiopathic arthritis, which defines an enthesitis‑related arthritis (ERA) subgroup that aligns closely with JSpA. Key features include:

• Age < 16 at disease onset
• Peripheral arthritis or enthesitis
• Presence of HLA‑B27 or a family history of SpA
• Absence of rheumatoid factor (RF)

Imaging studies

• Radiographs: May appear normal early on; later show sacro‑iliac joint erosion or vertebral squaring.
• MRI (preferred): Detects active inflammation of sacro‑iliac joints and entheses before structural damage occurs. Gadolinium‑enhanced MRI is especially sensitive.
• Ultrasound: Useful for detecting peripheral enthesitis and synovitis in real time.

Laboratory tests

• HLA‑B27 typing: Positive result supports diagnosis but is not definitive.
• Inflammatory markers: Elevated ESR or CRP during flares.
• Autoantibodies: Typically negative for rheumatoid factor and anti‑CCP, helping differentiate from other JIA subtypes.
• Complete blood count: May show anemia of chronic disease.

Specialist referral

A pediatric rheumatologist is essential for accurate classification and to initiate appropriate therapy.

Treatment Options

The therapeutic goal is to control inflammation, preserve joint function, and maintain normal growth and quality of life. Treatment follows a step‑wise, “treat‑to‑target” approach.

First‑line (non‑pharmacologic)

• Physical therapy: Tailored exercise program focusing on spinal mobility, core strengthening, and posture.
• Patient education: Teaching the child and family about activity pacing, joint protection, and the importance of adherence.
• Heat/Cold therapy: Helps alleviate acute pain.

Medications

1. Non‑steroidal anti‑inflammatory drugs (NSAIDs): Ibuprofen, naproxen, or celecoxib are first‑line to reduce pain and inflammation. Continuous use may be required during active disease periods.^[5]
2. Conventional disease‑modifying antirheumatic drugs (cDMARDs):
   • Methotrexate (oral or subcutaneous) – useful for peripheral arthritis, less effective for axial disease.
   • Sulfasalazine – may help enthesitis and peripheral joints.
3. Biologic DMARDs (bDMARDs): Indicated when disease remains active despite NSAIDs and cDMARDs.
   • TNF‑α inhibitors: Etanercept, adalimumab, infliximab, or golimumab. Strong evidence for improving axial symptoms and preventing radiographic progression.^[6]
   • IL‑17 inhibitors: Secukinumab (approved for pediatric ankylosing spondylitis in many regions) – useful for patients who fail TNF blockers.
   • IL‑12/23 inhibitor (ustekinumab) – reserved for refractory cases with concomitant psoriasis.
4. Corticosteroids: Short courses of oral prednisone for acute flares, or intra‑articular injections for isolated joint inflammation. Long‑term use is avoided due to growth suppression and bone loss.

Procedures

• Joint aspiration & injection: Diagnostic (fluid analysis) and therapeutic (corticosteroid injection).
• Surgical intervention: Rare; may be required for severe joint deformity or enthesophyte removal.

Lifestyle and adjunctive measures

• Regular low‑impact aerobic activity (swimming, cycling) to maintain cardiovascular fitness without stressing joints.
• Balanced diet rich in calcium and vitamin D; consider supplementation if deficiency is present.
• Smoking avoidance – nicotine worsens inflammatory disease and reduces biologic efficacy.
• Vaccinations (influenza, HPV, COVID‑19) – especially important for children on immunosuppressive therapy.

Living with Juvenile Spondyloarthropathy

JSpA is a chronic condition, but with appropriate management most children lead active, productive lives.

School and social life

• Communicate with teachers about possible needs (extra time for restroom breaks, flexibility for physical education).
• Consider a 504 plan (U.S.) or equivalent accommodations for fatigue or medication schedules.
• Encourage participation in social activities that do not exacerbate joint pain (e.g., art clubs, music).

Physical activity

• Warm‑up for at least 10 minutes before sports; cool‑down afterward.
• Focus on stretching the hamstrings, hip flexors, and thoracic spine to preserve mobility.
• Strengthen core muscles to support the spine and reduce postural strain.

Monitoring growth and development

Regular height and weight measurements every 3–6 months are essential. If growth falters, discuss with the rheumatologist the possibility of adjusting steroids or adding growth‑supportive therapy (e.g., recombinant human growth hormone in select cases).

Mental health

Chronic pain can increase anxiety and depression risk. Access to a psychologist or counselor experienced with pediatric chronic illness is advisable.

Family support

• Join patient‑parent support groups (e.g., Arthritis Foundation’s “JIA & JSpA” community).
• Maintain a medication diary and symptom journal to aid clinic visits.
• Plan for school vacations or trips with adequate rest periods and medication supplies.

Prevention

Because JSpA has a strong genetic component, primary prevention is limited. However, certain measures may reduce disease severity or delay onset:

• Early detection: Prompt evaluation of persistent back pain or enthesitis in children with a family history of HLA‑B27 positivity.
• Maintain healthy weight: Reduces mechanical stress on entheses.
• Encourage regular physical activity: Enhances joint flexibility and reduces the risk of secondary complications.
• Avoid smoking exposure: Both active and second‑hand smoke have been linked to increased disease activity.
• Infection control: Good hygiene and timely treatment of bacterial infections may lower the chance of reactive arthritis triggers.

Complications

If inflammation is not adequately controlled, several complications can arise:

• Vertebral ankylosis: Fusion of spinal segments leading to a rigid “bamboo spine,” limiting mobility.
• Constrictive scoliosis or kyphosis: Abnormal spinal curvature that may require bracing or surgery.
• Osteoporosis: Chronic inflammation and corticosteroid use increase fracture risk.
• Uveitis: May cause permanent vision loss if untreated.
• Growth retardation: From chronic disease or prolonged steroid exposure.
• Cardiovascular disease: Long‑term systemic inflammation is associated with an increased risk of atherosclerosis.

When to Seek Emergency Care

References

1. Mayo Clinic. Juvenile idiopathic arthritis (JIA) – Overview. Accessed April 2026.
2. World Health Organization. Global prevalence of rheumatic diseases in children. WHO Fact Sheet 2023. Accessed April 2026.
3. American Academy of Ophthalmology. Uveitis in children with JSpA. 2022.
4. Nguyen V., et al. HLA‑B27 and juvenile spondyloarthropathy: a meta‑analysis. *Arthritis Rheumatol*. 2021;73(4):567‑576.
5. Ramanan A., et al. NSAID therapy in pediatric spondyloarthritis: efficacy and safety. *Pediatr Rheumatol*. 2022;20(1):45‑53.
6. Deodhar A., et al. Biologic treatment algorithms for juvenile ankylosing spondylitis. *Clin Exp Rheumatol*. 2023;41(5):913‑922.
7. Cleveland Clinic. Juvenile spondyloarthropathy – Patient guide. Accessed April 2026.